These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19641174)

  • 1. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
    Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
    J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
    Lee JW; Stone RL; Lee SJ; Nam EJ; Roh JW; Nick AM; Han HD; Shahzad MM; Kim HS; Mangala LS; Jennings NB; Mao S; Gooya J; Jackson D; Coleman RL; Sood AK
    Clin Cancer Res; 2010 May; 16(9):2562-70. PubMed ID: 20388851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
    Jackson D; Gooya J; Mao S; Kinneer K; Xu L; Camara M; Fazenbaker C; Fleming R; Swamynathan S; Meyer D; Senter PD; Gao C; Wu H; Kinch M; Coats S; Kiener PA; Tice DA
    Cancer Res; 2008 Nov; 68(22):9367-74. PubMed ID: 19010911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.
    Song JX; Li FQ; Cao WL; Jia X; Shi LN; Lu JF; Ma CF; Kong QQ
    Target Oncol; 2014 Sep; 9(3):263-72. PubMed ID: 23943313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
    Oflazoglu E; Stone IJ; Gordon K; Wood CG; Repasky EA; Grewal IS; Law CL; Gerber HP
    Clin Cancer Res; 2008 Oct; 14(19):6171-80. PubMed ID: 18809969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
    Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
    J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
    Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
    J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
    Doñate F; Raitano A; Morrison K; An Z; Capo L; Aviña H; Karki S; Morrison K; Yang P; Ou J; Moriya R; Shostak Y; Malik F; Nadell R; Liu W; Satpayev D; Atkinson J; Joseph IB; Pereira DS; Challita-Eid PM; Stover DR
    Clin Cancer Res; 2016 Apr; 22(8):1989-99. PubMed ID: 26589436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
    Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
    Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.
    Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
    Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
    Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of EphA2 and FAK in ovarian carcinoma.
    Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
    Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
    Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
    Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.